Drug-Induced Interstitial Lung Disease in a patient treated with a combination of palbociclib and fulvestrant
Chest Disease Reports · 2023
DOI: 10.4081/cdr.11.11679 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chest Disease Reports, 2023. Verfasst von Maria Angela Vittoria Licata und 3 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
A 59-year-old patient without a history of pulmonary disease presented with episodes of hemoptysis and acute respiratory failure after being treated for metastatic breast cancer with fulvestrant and palbociclib. The high-resolution chest CT revealed diffuse ground glass opacities and diffuse smooth thickening of the interlobular septa and peribronchovascular interstitium, consistent with drug-induced interstitial lung disease (DIILD). A few days of high-dose steroid treatment increased the patient's PaO2/FiO2 from 75 to 200. Following hospital discharge, the oncologist resumed fulvestrant therapy, with no further adverse events occurring during subsequent follow-up.
Zitieren
APA
Licata, M. A. V., Porro, L. M., Sgalla, G., & Richeldi, L. (2023). Drug-Induced Interstitial Lung Disease in a patient treated with a combination of palbociclib and fulvestrant. Chest Disease Reports. https://doi.org/10.4081/cdr.11.11679
Vancouver
Licata MAV, Porro LM, Sgalla G, Richeldi L. Drug-Induced Interstitial Lung Disease in a patient treated with a combination of palbociclib and fulvestrant. Chest Disease Reports. 2023. doi:10.4081/cdr.11.11679
BibTeX
@article{Licata2023,
author = {Licata, Maria Angela Vittoria and Porro, Lucia Maria and Sgalla, Giacomo and Richeldi, Luca},
title = {Drug-Induced Interstitial Lung Disease in a patient treated with a combination of palbociclib and fulvestrant},
journal = {Chest Disease Reports},
year = {2023},
doi = {10.4081/cdr.11.11679}
}
EUVIMED